<DOC>
	<DOC>NCT03017885</DOC>
	<brief_summary>This active surveillance will include all NSCLC patients treated with nintedanib per the inclusion/exclusion criteria at approximately 20 selected centers until it is confirmed that 100 patients treated with nintedanib are included and that baseline characteristics of 100 additional patients (or as many patients as in the nintedanib group if &lt;100) planned to be treated with single agent docetaxel are collected from the same centres during the same time frame, or until a maximum of two years, whichever occurs first</brief_summary>
	<brief_title>Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Patients â‰¥18 years of age with locally advanced and/or metastatic NSCLC of stage IIIB or IV, or recurrent NSCLC and adenocarcinoma histology after relapse or failure of first line of chemotherapy who are newly prescribed nintedanib according to the package insert Willing to provide the informed consent Patients in whom further visit/contact is possible during the planned period of active surveillance Patients who have taken nintedanib before participation in the study Patients who are positive for endothelial growth factor receptor mutation Patients who are positive for anaplastic lymphoma kinase rearrangements Patients who are participating in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>